Abstract
Breast cancer is the women's second cause of deaths in the world. The few molecular markers used in the clinical breast cancer diagnosis are still not enough to allow the most adequate clinical and surgical treatment. The genetic heterogeneity presented in the patients and in the tumors also limit the prediction of clinical outcome during the evolution of the disease. In this sense, the s…